Roquefort Therapeutics plc
ROQ.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | £1,845 | £5,258 | £6,135 | £9,895 |
| - Cash | £183 | £337 | £596 | £537 |
| + Debt | £384 | £400 | £610 | £0 |
| Enterprise Value | £2,046 | £5,321 | £6,149 | £9,357 |
| Revenue | £0 | £0 | £3 | £0 |
| % Growth | – | -100% | – | – |
| Gross Profit | £0 | -£3 | -£16 | -£5 |
| % Margin | – | – | -592.2% | – |
| EBITDA | -£491 | -£436 | -£675 | -£994 |
| % Margin | – | – | -24,999.6% | – |
| Net Income | -£490 | -£392 | -£580 | -£962 |
| % Margin | – | – | -21,447.1% | – |
| EPS Diluted | -0.003 | -0.003 | -0.005 | -0.007 |
| % Growth | -10% | 33.3% | 36.6% | – |
| Operating Cash Flow | -£330 | -£259 | -£525 | -£845 |
| Capital Expenditures | -£57 | £0 | -£0 | £0 |
| Free Cash Flow | -£386 | -£259 | -£525 | -£845 |